Premium
Continuing barriers to care of Wilms tumor in a low‐income country
Author(s) -
Ekenze Sebastian O.,
Nwangwu Emmanuel I.,
Ezomike Uchechukwu O.,
Orji Emmanuel I.,
Okafor Okechukwu O.
Publication year - 2019
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.27416
Subject(s) - medicine , referral , chemotherapy , wilms' tumor , radiation therapy , regimen , chemotherapy regimen , surgery , pediatrics , family medicine
Background/objective This study evaluates the outcome of Wilms tumor (WT) following introduction of multidisciplinary team management and patient treatment stratification by tumor histology in two referral centers in southeastern Nigeria. Methods We analyzed histologically confirmed WT cases managed from January 2008 to June 2017. Results There were 45 patients, peak age incidence of 2 to 5 years who presented after mean symptom duration of 4.9 months (range, 1–12 months), with mean tumor weight of 1040 g (range, 350–4200 g). Overall, 14 (31.1%) had unfavorable histology of WT. A total of 22 (48.9%) patients received preoperative chemotherapy, 43 (95.6%) received postoperative chemotherapy based on stage of disease and histopathology, but none received adequate radiotherapy. Of these, 19 (44.2%) patients complied with chemotherapy regimen, 15 (33.3%) were lost to follow‐up and 12 (26.7%) cases relapsed. With 30 cases available for evaluation and mean follow‐up duration of 23 months (range, 6–80 months), the overall 5‐year survival is 53.3% (16 cases). Survival in children who complied with postoperative chemotherapy was 73.7%, and abandonment‐sensitive survival was 35.6%. Persisting challenges were late presentation, poor compliance to treatment, and lack of radiotherapy treatment. Conclusion Multidisciplinary team management and chemotherapy based on tumor histology might have resulted in slight improvement of outcome since our last report. However, to ensure survival that may approach global benchmarks, there is need for public health measures to improve time to diagnosis, and improvement of facilities and healthcare funding to ensure compliance to all phases of standard therapy.